National Institute of Mental Health, Contracts Management Branch, 5600 Fishers Lane, Rm. 9C-15, Rockville, MD, 20857-8030

A -- NIMH PSYCHOACTIVE DRUG SCREENING PROGRAM SOL NIMH-98-DB-0005 DUE 061198 POC Contracting Officer, David Eskenazi, (301) 443-2696 WEB: NIMH Psychoactive Drug Screening Program, http://www.nimh.nih.gov/grants/rfp.htm. E-MAIL: Click here to contact the contracting officer via e-mail, de5d@nih.gov. The National Institute of Mental Health proposes to issue a solicitation (RFP) No. NIMH-98-DB-0005 entitled "NIMH Psychoactive Drug Screening Program" as Full and Open Competition under SIC Code 8734. The NIMH plans to award a three year (one base year and two one-year options) cost-reimbursement contract, and plans to make the award by September 30, 1998. This will be the initial award for this requirement. The purpose of this contract is to provide pharmacological and functional screening of novel synthetic compounds and natural products for potential use as PET ligands for functional brain imaging, research tools or probes for preclinical research, and therapeutic agents for mental disorders. This screen is not intended for the purpose of large-scale, random screening of natural products or combinatorial libraries but is intended as a screen for compounds that have previously been shown to possess novel pharmacological, biochemical, or behavioral activities relevant to NIMH. The objectives of the contract will be to receive and test approximately 200 to 300 NIMH-approved and coded samples (synthetic compounds, gene products, and natural product extracts) per year in primary broad-based CNS receptor and enzyme screening assays, to test active samples in secondary functional assays, and to provide an electronic data file for each of the screened compounds. Approximately 50% of these samples are to be tested in human recombinant receptor assays. Samples for screening can include, but are not limited to, novel chemical entities, structural analogs of lead compounds, genes or gene products, small molecules, enzyme inhibitors, and natural products. It is anticipated that NIMH-approved and coded samples will be submitted from a variety of sources including NIH-funded research programs, pharmaceutical companies, biotechnology companies, or other sources. It is expected that the screening information derived from this program will provide individual investigators with conceptual or structural leads for the design and/or development of new chemical entities, small molecules, genes or gene products, therapeutic entities, or PET/SPECT ligands for human brain imaging. Request for Proposal (RFP) No. NIMH-98-DB-0005 will be available on or about April 22, 1998 and the receipt date of proposal on or about June 11, 1998. The RFP may be accessed through the NIMH Home Page by using the following instructions: access the home page at http://www.nimh.nih.gov, first select "Grants and Contracts", then select "NIMH Request for Proposals (RFP)", and lastly select "NIMH-98-DB-0005." Please note that the RFP for this requirement will include the Statement of Work, Deliverables and Reporting Requirements, the Technical Evaluation Criteria, and proposal preparation instructions. All information required for the submission of an offer will be contained in the electronic RFP package. Following proposal submission and initial review process, offerors comprising of the competitive range will be requested to provide additional documentation to the Contracting Officer. All responsible sources may submit a proposal that will be considered by the NIMH. This advertisement does not commit the Government to award a contract. (0099)

Loren Data Corp. http://www.ld.com (SYN# 0006 19980413\A-0006.SOL)